Products
Cusatuzumab Biosimilar Monoclonal Antibody (CD70) for Research
Pre-Made Cusatuzumab biosimilar, Whole mAb, Anti-CD70/CD27-L Antibody: Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-127-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Cusatuzumab biosimilar, Whole mAb, Anti-CD70/CD27-L Antibody: Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A therapeutic antibody |
| INN Name | Cusatuzumab |
| Target | CD27-L |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | arGEN-X |
| Conditions Approved | na |
| Conditions Active | Cutaneous T-cell lymphoma;Acute myeloid leukaemia;Haematological malignancies;Myelodysplastic syndromes;Solid tumours |
| Conditions Discontinued | Nasopharyngeal cancer;Autoimmune disorders |
| Development Tech | POTELLIGENT Technology;SIMPLE Antibody Technology |
About target - CD70
1. Protein CD70 antigen
2. Gene CD70
3. Organism Homo sapiens (Human)
Function
Cytokine which is the ligand for CD27. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells.
